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Interindividual Variation in Carcinogen
Metabolism and Bladder Cancer Risk
by Paolo Vineis and Guglielmo Ronco2
Epidemiological studies indicate that subjects ofthe genetically based slow acetylatorphenotype maybe at
higher risk for bladder cancer than fast acetylators, particularly when they are exposed to carcinogenic
arylamines: N-acetylation is a detoxification step in the metabolism of some arylamines. We describe two
collaborative studiesontobacco smoking, in which markersofinternaldose(arylamine-hemoglobin adducts)
and markers of genetically based metabolic polymorphism have been coupled. In the first investigation, we
found that hemoglobin adducts formed by mononuclear arylamines have high reciprocal correlation coeffi-
cients, as do adducts from binuclear arylamines. This tendency of adducts with structurally similar
arylamines tocorrelatereciprocallyexplains alargeproportionoftheresidualvarianceseenaftercontrolling
for smoking habits (number and type of cigarettes). In the second study, the concentration of 4-amino-
biphenyl-hemoglobin adductsvariedaccordingtothreeindependentdeterminants: numberofcigarettes,type
of tobacco (air or flue cured), and acetylator phenotype (slow and fast). The dose-response relationship
between the amount of tobacco smoked and level of 4-aminobiphenyl-hemoglobin adducts in the slow
acetylators (with an immediate steep increase ofthe adducts) was different from that in the fast acetylators
(with a more regular increase). These findings from "molecular epidemiology" may contribute to an
understanding ofthe role ofmetabolic polymorphism in human carcinogenesis.
Introduction
Interindividual variability in the metabolism of aryl-
amines has been suggested in several epidemiological
investigations tobe relevantto humanbladder cancer. The
purpose ofthis paperistoreviewsuchevidencebrieflyand
to report the relevant findings of two studies on the
"molecular epidemiology" ofbladder cancer.
Epidemiological Evidence on
N-Acetyltransferase Polymorphism
and Bladder Cancer Risk
N-Acetyltransferase is involved in the detoxication of
arylamines, a class of chemicals that includes some well-
known bladder carcinogens. The activity of the enzyme
shows genetically based polymorphism in human popula-
tions, with a clear-cut distinction between extensive
metabolizers, who compose about 30-50% of the popula-
tion, and poor metabolizers (PM), who represent 50-70%
ofthe general population inwestern countries. Since some
arylamines arepotentbladdercarcinogens andN-acetyla-
tion is involved in their detoxication, one would expect PM
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to be at higher risk for bladder cancer than extensive
metabolizers.
Intheirseminalreport, Cartwrightetal. (1)describeda
case-control study of 111 bladder cancer cases and 207
controls. The N-acetylation phenotype was assessed by
measuringthemonoacetyldapsone: dapsone ratio, and 0.3
wasused asthecut-offpointbetweenthephenotypes.The
proportion of PM was 57% among the controls and 67%
among the cases; however, this proportion was consider-
ably increased in a group of 23 occupationally exposed
cases (with possible exposure to benzidine and 2-naph-
thylamine). In fact, 22 out of23 (p = 0.005) were PM; the
onlyfastmetabolizer had an adenocarcinoma, i.e., ahisto-
logic type different from that ofthe other 22, which were
transitional-cell carcinomas.
Theveryhighproportion ofpooracetylators amongthe
occupationallyexposed bladder cancer cases describedby
Cartwright et al. has not been reported by others. A
number of case-control studies have shown, however, a
slight excess of PM among bladder cancer patients in
comparisonwithcontrols.Table 1 givestheresultsofthese
studies. The numbers are generally small, and the confi-
dence intervals ofthe odds ratios are large; nevertheless,
the qualitative consistency of the findings is intriguing
(see also reference 4 for a review). Overall, these data are
compatible with an increased risk for bladder cancer of
around 30% among PM, a figure much lower than that
reported by Cartwright et al. Possible explanations for
this seriesofobservations andfortheirinconsistencywith
those ofCartwright et al. are the following: a) There mayVINEIS AND RONCO
Table 1. Proportion (%) of slow acetylators among bladder cancer
cases and controls in different studies.a
Cases Controls
Location % No. % No.
Denmark 65 71 51 74
Huddersfield, UK 67 111 57 95
Rural Sweden 70 115 67 118
Wisconsin, USA 59 34 49 41
NewYork State, USA 46 26 69 26
Newcastle, UK 70 30 59 27
Liverpool, UK 66 66 60 510
Rural Denmark 64 228 54 100
Spain (3) 64 130 57 157
Spain (exposed to arylamines) 73 11 - -
aFrom Mommsen et al. (2) and Ladero et al. (3).
be a common bias in the studies. In fact, most of the
investigations reported in Table 1 included both incident
and prevalent cases; if the PM phenotype is associated
mainly with survival, then the excess ofPM among blad-
der cancer patients would be due entirely to the prevalent
cases. This explanation, however, does not hold for the
study of Cartwright et al. Other sources of bias are
unlikely, since methods for phenotyping are reliable and
N-acetyltransferase is not inducible. Chance is also very
unlikely to explain the observations. b) If the PM phe-
notype is relevant only to arylamine-induced bladder can-
cer,thedifferentproportions ofPM amongthe casesinthe
differentinvestigations mightbebecause different propor-
tions of subjects were exposed to arylamines. In fact, a
higher proportion ofPM was present among the cases in
the Spanish study when only workers with potential
exposure to arylamines were selected. c) The populations
that have been studied had qualitatively different
exposures toarylamines. Forexample,theBritishworkers
studied by Cartwright et al. were probably exposed to
high levels ofbenzidine and 2-naphthylamine; the nature
of the occupational exposure in the study in Spain is
uncertain. Tobacco smoke contains varying amounts of
arylamines, including 4-aminobiphenyl (4-ABP) and 2-
naphthylamine, and the composition of tobacco smoke is
different in different countries, according to the type of
tobacco used (5).
Hemoglobin Adducts Formed by
Arylamines: Interindividual Variability
According to Chemical Structure
In a molecular epidemiology investigation in which we
wereinvolved (6), wereported thatthe quantities ofhemo-
globin adducts with 3-aminobiphenyl (3-ABP) and 4-ABP
were related to the quantity ofcigarettes smoked and, in
the case of4-ABP, also to the kind oftobacco smoked (air
orfluecured).Air-curedtobaccoisknowntocontainlarger
amounts of arylamines than flue-cured product and has
also been found to be associated with higher risks of
bladder cancer in three epidemiological investigations (7-
9).
In the molecular epidemiology investigation, the quan-
tity and type oftobacco smoked were statistically signifi-
cantly associated to the quantity of 4-ABP-hemoglobin
adducts but could not explain a considerable proportion of
theinterindividualvariationintheamountsofadducts.We
reanalyzed the same set of data for smokers in order to
ascertain whetherthe residual, unexplainedvariationwas
related to individual differences in susceptibility, possibly
due to metabolic characteristics. If individual metabolic
differences were responsible for part of the unexplained
interindividual variation in the levels of hemoglobin
adducts andifchemically similarsubstances have, atleast
in part, common metabolic pathways, then the concentra-
tions ofadducts with similar amines should be correlated
inthe sameindividual, allowingfortheamountandtype of
tobacco smoked. In otherwords, subjects with high levels
of 4-ABP adducts should also have high levels of 3-ABP
adducts, allowing for tobacco consumption, and subjects
with low levels of4-ABP should have low levels of3-ABP.
We considered the data for 25 nonsmokers, 18 smokers
ofair-curedtobacco, and40smokersofflue-curedtobacco,
all living in the city ofTorino (Thrin). Blood samples were
analyzed at the Massachusetts Institute of Technology
(Cambridge) for hemoglobin adducts formed with 14 aro-
matic amines, using gas chromatography-mass spec-
trometry. The distribution of subjects by number of
cigarettes smoked the day before collection is shown in
Table 2.
For all quantities, except for 3, 8, 12, 14, 16, 17, and 18
cigarettes, atleasttwo subjectsreported exactlythe same
amount smoked. Only these 54 subjects were included in
thestatisticalanalysesasatleasttwosmokersofthesame
amount were necessary to study interindividual vari-
ability not explained by the amount smoked. Amodel was
fitted by the least-squares method for each aromatic
amine, including the kind and amount oftobacco smoked;
statistical residuals from this model were computed.
Residuals are the differences between the observed levels
of adducts and those expected on the basis ofthe model.
This procedure is equivalent to computing the difference
between the amount of adducts in each subject and the
mean for all subjects who smoked exactly the same num-
berofcigarettes, afteradjustingforkindoftobacco. Since,
Table 2. First study on arylamine-hemoglobin adducts: distribution
ofsubjects by number ofcigarettes smoked.
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forall amines, the residuals showed alog-normal distribu-
tion, the logarithm ofadduct concentration was also used.
Acorrelation matrix ofthe residuals forthe 14 aromatic
amines was computed, and aprincipal component analysis
was performed. The purpose ofprincipal component anal-
ysis is to determine factors (i.e., principal components) in
such a way as to explain as much ofthe total variation in
the data as possible. The results of this analysis are
reported in Table 3. Within each principal component
("factor"), the correlation coefficient of each arylamine
with the factor is reported. The first principal component
explains 49% of total variance and is related to all sub-
stances except 3-ABP, 4-ABP, and 2-naphthylamine; the
second principal component explains a further 16% ofthe
total variance and includes 3-ABP, 4-ABP, and 2-naph-
thylamine, whereas the coefficients for all other amines
(exceptp-toluidine) are negative or close to zero. Compar-
able results are obtained ifthe log (adducts) are analyzed
instead ofresiduals. Further details have been published
elsewhere (10).
Our hypothesis was that individual metabolic dif-
ferences, representedbythe correlations between adducts
with different aromatic amines, could explain part of the
interindividual variability that is not explained by the
characteristics ofsmokinghabits. The results we obtained
are clearly in agreement with this hypothesis, since the
correlation among one group ofresiduals explained 49% of
the total variance ofresiduals, and the correlation among
residuals of a second group explained afurther 16% ofthe
variance. Interestingly, the variables that contribute to
thefirstprincipal component areallmononucleararomatic
amines, and those included in the second component are
binuclear amines (3-ABP, 4-ABP, 2-naphthylamine).
Residuals of compounds in one group (e.g., mononuclear)
are correlated with residuals of other amines within the
same group (i.e., subjects who have higher levels of one
compound than expected have higher levels of the other
compounds too) but are independent of residuals of com-
pounds in other groups.
This finding seems to suggest that two different meta-
bolic pathways are involved-one for mononuclear and the
other for binuclear aromatic amines-and that interin-
dividual variability exists for these pathways. Such vari-
ability would explain a considerable proportion of the
differences in levels of hemoglobin adducts that are not
explained by smoking habits.
N-Acetyltransferase Polymorphism
and 4-ABP-Hemoglobin Adducts
Several sources of information indicate that 4-ABP is
related to bladder carcinogenesis in smokers: two studies
on hemoglobin adducts, including that already mentioned
(6,11); one study on DNA adducts in exfoliated bladder
cells (12); one study of bladder biopsy samples from
humans (13); and studies on bladder biopsy samples from
dogs. Thlaska et al. (14) showed that administration of
4-ABPtodogsresultedinformationofamainDNAadduct
in bladder cells, N-(deoxyguanosin-8-yl)-4-ABP. Subse-
quently, theystudiedDNAadductsinbiopsysamplesfrom
42 subjects with bladder cancer and again found that
N-(deoxyguanosin-8-yl)-4-ABP was one of the main ad-
ducts in smokers (13). Finally, a comprehensive collabora-
tiveinvestigationhasbeenconducted among97volunteers
in Torino to measure the levels of 4-ABP adducts with
hemoglobin (11) and with DNA in exfoliated bladder cells
(12). The levels of hemoglobin adducts clearly correlate
with the number of cigarettes smoked, with urinary
cotinine and nicotine, and with the type of tobacco used
(air orfluecured). In addition, thelevels of2 outof12 DNA
adducts found among smokers were clearly correlated
with both the number of cigarettes smoked and the con-
centration of4-ABP-hemoglobin adducts; one of the two
DNA adducts was quite similar to N-(deoxyguanosin-8-
yl)-4-aminobiphenyl (12). There are good reasons to
believe, therefore, that 4-ABP, and perhaps other aryl-
amines,play animportantroleinsmoking-induced bladder
carcinogenesis.
In the study mentioned above on 97 volunteers, the
concentration of 4-ABP-hemoglobin adducts was also
measured according to N-acetylation phenotype (defined
on the basis of the ratio of two metabolites of caffeine,
5-acetylamino-6-formylamino-3-methyluracil, and 17-
methylxanthine; measurementsmadeatthe NationalCen-
Table 3. Principal component analysis ofresiduals for 14 aromatic aminesa (weights ofresiduals for each substance in the first 7 factors).
Substance Factor 1 Factor2 Factor 3 Factor 4 Factor5 Factor 6 Factor 7
4-ABP 0.07 0.32 0.56 0.11 0.47 -0.44 -0.11
3-ABP 0.07 0.52 0.18 -0.13 0.25 0.62 0.33
2-Naphthylamine 0.01 0.52 0.06 0.21 -0.51 -0.37 -0.32
o-lbluidine 0.22 0.05 -0.03 0.73 0.01 0.26 -0.35
m-Toluidine 0.32 0.13 0.04 -0.01 -0.08 -0.05 -0.54
p-lbluidine 0.23 0.38 -0.25 -0.15 -0.30 0.19 -0.22
2,4-Dimethylamine 0.27 0.01 -0.40 0.13 0.42 0.01 0.13
2,6-Dimethylamine 0.22 -0.13 0.49 -0.35 -0.11 0.23 -0.24
2,3-Dimethylamine 0.33 -0.18 0.16 -0.07 -0.30 -0.04 0.09
3,5-Dimethylamine 0.34 -0.01 -0.15 -0.23 0.21 -0.23 0.04
3,4-Dimethylamine 0.34 0.05 -0.21 -0.16 0.09 -0.25 0.00
2,5-Dimethylamine 0.31 -0.28 0.19 0.13 -0.16 0.07 0.28
3-Ethylamine 0.36 0.07 -0.13 -0.16 -0.01 -0.01 0.17
2-Ethylamine 0.30 -0.23 0.20 0.30 0.02 0.05 0.35
Proportion oftotal variance 49% 16% 10% 7% 5% 4% 3%
Abbreviations: 4-ABP, 4-aminobiphenyl; 3-ABP, 3-aminobiphenyl.
aFromRonco et al. (10).
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ter for Toxicological Research, Jefferson, AR). The con-
centration ofadducts is clearly higher in slow acetylators
(Table4).Whensmokinghabits (dose,typeoftobacco) and
metabolic phenotype were included in a multivariate
model, an independent, statistically significant contribu-
tion of the latter was found. This finding agrees with a
priori expectations, since N-acetylation is expected to




ogy has usually been interpreted to infer the number of
stages in the carcinogenic process, within the frame of
multistage carcinogenesis. An example is the quadratic
dose-response relationship seen between the number of
cigarettes smoked and the risk for lung cancer; the
inference is that tobacco smoke acts at two stages ofthe
carcinogenic process in the lung (15). The dose-response
relationship canalsobeanexpression ofotherphenomena;
one ofthese is metabolic polymorphism within the study
population, i.e., the presence of subgroups with different
susceptibilities to the action ofcarcinogens.
In epidemiological studies of bladder cancer, a convex
dose-response relationship has been observed repeatedly
between the number ofcigarettes smoked andtherelative
risk, rather than the linear or exponential curve seen in
lungcancer(16). Inotherwords, therelativeriskincreases
quickly, then seems toreach aplateau. Forexample, inthe
largest case-control study reported, the relative risks by
number of cigarettes smoked (with nonsmokers as the
reference category) were: < 20, 1.8 (based on 658 cases);
20-39, 2.6 (1102 cases); and 2 40, 2.6 (392 cases) (17). In a
Danish investigation, the following relative risks were
found: for1-14cigarettes, 4.2;15-29,4.9; and 2 25,4.3(18).
Inotherinvestigations, however, theplateauwasless clear
(16).
Aconvexdose-response curvewasalsoobservedforthe
correlation of the concentration of 4-ABP-hemoglobin
adducts with markers ofrecent smoking (number ofciga-
rettes, urinary cotinine and nicotine) (6,11). Such a rela-
tionship would be expected a priori if the population
included two subgroups-one that metabolizes the rele-
vant chemical rapidly and the other, slowly. In fact, when
the data on hemoglobin adducts were subdivided accord-
ing to metabolic phenotype (slow or fast acetylator), the
pictureshowninTable5emerged. Slowacetylatorsclearly
have a high level of adducts at low levels of smoking,
Table 4. Means (and SEs) ofconcentrations of4-aminobiphenyl-
hemoglobin adducts in blood ofsmokers ofblack and blond
tobacco and ofnonsmokers (pg/g hemoglobin),
by acetylation phenotype.a
Acetylation phenotype Ratio
Smoking status Slow Fast slow:fast
Nonsmoker 31.7 (3.8) 19.4 (4.9) 1.6
Blond tobacco 111.8 (13.0) 86.4 (14.5) 1.3
Black tobacco 175.0 (11.0) 117.5 (13.7) 1.5
aFrom Bartsch et al. (11).
lible 5. Levels of4-aminobiphenyl-hemoglobin adducts according
to level ofcotinine plus nicotine in urine, by metabolic phenotype,
smokers only.
Cotinine plus nicotine, Adducts, pg/g (mean ± SE)
p.mole/mmole Fast acetylators Slow acetylators
< 0.5 44a 153 ± 41
0.5-1.4 66 ± 12 114 ± 17
1.5-2.4 92 ± 36 134 ± 15
> 2.5 121 ± 16 148 ± 20
a One subject only.
whereas the curve for fast acetylators increases more
regularly. The association ofthe two curves leads to aless
thanlinearrelationship.Theinterceptofthecurveforslow
acetylators is 72 pg/g hemoglobin, which is significantly
differentfromtheinterceptforfastacetylators (p = 0.01).
Unfortunately, these observations are still based on small
numbers, as expressed by the large standard errors in
Table 5, and warrant further investigation.
It would be an oversimplification to conclude that the
convex dose-response curve observed between the num-
ber ofcigarettes smoked and the relative risk for bladder
cancerindicatesthesamephenomenon ashypothesizedfor
hemoglobin adducts. In fact, carcinogenesis is more com-
plex than the simple binding of arylamines to mac-
romolecules. Nevertheless, the similarity of the dose-
response curves is suggestive.
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